Dear OncoLink "Ask The Experts,"
I had lung cancer in my left lung in 1987, and was treated with chemo and radiation for a year. I recovered and am doing great. I have been wondering: I thought I had heard that all the chemo and radiation can age your bones by about 10 years?? I would like to know what you think.
Linda Jacobs, PhD, CRNP, AOCN, BC, Clinical Assistant Professor at the University of Pennsylvania School of Nursing, responds:
The bone issue you mention is primarily related to the chemotherapy. Bone health is affected by hormones, or rather a lack of them. A premenstrual woman who has no menstrual periods for 1 full year after the completion of chemotherapy is considered to have "ovarian failure". If a woman experiences ovarian failure from chemotherapy, she should have a DEXA scan to evaluate bone mineral density (a measure of bone health and osteoporosis). If the scan suggests osteopenia (weakened bone) or osteoporosis, treatment to strengthen bone and prevent fractures is warranted. In general, all women should be counseled on taking calcium with Vitamin D, (unless they have medical contraindications to such therapy), in order to help maintain whatever bone density they currently have. Weight-bearing exercise is also recommended to improve bone health. If a woman has naturally occurring menopause (which is basically natural "ovarian failure"), the same recommendations apply, including a DEXA scan 1 year after cessation of menses.
Primary care providers or gynecologists can order DEXA scans and follow up with you regarding the results and any subsequent management (such as the need for Fosamax or Actinol osteoporosis treatment), if osteopenia or osteoporosis is noted.
Dec 7, 2010 - Rituximab may be a better option than watchful waiting in some lymphoma patients, and a new treatment option appears effective for relapsed or refractory Hodgkin's lymphoma, according to two studies being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. Other research being presented will highlight new options for the standard treatment of advanced asymptomatic follicular lymphoma; mantle cell lymphoma; and early, unfavorable Hodgkin's disease.
Jul 9, 2010
Mar 17, 2010